Clinical Trials to Validate AI-Driven Drug Repurposing 2026
Supports early-phase clinical trials validating AI-driven drug repurposing for unsolved and rare diseases, requiring explainable AI workflows and collaboration between clinicians and data scientists.
Funder: Cures Within Reach
Due Dates: June 26, 2026: Letter of Intent (LOI) submission deadline (11:59pm US Eastern Time)
Funding Amounts: Up to $100,000 per project (includes required 10% institutional match); additional $5,000–$10,000 for approved community engagement.
Summary: Supports global Phase I/IIA clinical trials to validate AI-driven drug repurposing for unsolved diseases, emphasizing rare diseases and explainable AI workflows.
Key Information: 2-stage process (LOI required); only accredited research institutions/health systems eligible; strong preference for rare diseases and off-patent therapies.
Description
This opportunity funds investigator-initiated, proof of concept, Phase I or Phase IIA clinical trials to validate artificial intelligence (AI)-driven drug repurposing opportunities for any unsolved disease, with a particular emphasis on rare diseases. Projects must use AI-generated data as preclinical support, and the AI workflow must clearly support the repurposing hypothesis and be explainable in a clinical context. Eligible therapies include approved drugs, biologics, eligible cellular/gene therapies, or combination therapies that are being tested for new indications. The funder encourages collaboration between clinical researchers and AI data scientists, as well as community engagement to enhance the impact and reach of funded trials.
